TWST vs. FUSN, RXRX, SANA, DNA, BEAM, NMRA, INBX, ADMA, KYMR, and VCEL
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Fusion Pharmaceuticals (FUSN), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), Neumora Therapeutics (NMRA), Inhibrx (INBX), ADMA Biologics (ADMA), Kymera Therapeutics (KYMR), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Fusion Pharmaceuticals has lower revenue, but higher earnings than Twist Bioscience. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. 3.9% of Twist Bioscience shares are owned by company insiders. Comparatively, 7.8% of Fusion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Twist Bioscience received 44 more outperform votes than Fusion Pharmaceuticals when rated by MarketBeat users. However, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 55.56% of users gave Twist Bioscience an outperform vote.
In the previous week, Twist Bioscience had 1 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 3 mentions for Twist Bioscience and 2 mentions for Fusion Pharmaceuticals. Fusion Pharmaceuticals' average media sentiment score of 0.56 beat Twist Bioscience's score of 0.48 indicating that Fusion Pharmaceuticals is being referred to more favorably in the news media.
Twist Bioscience presently has a consensus price target of $36.40, suggesting a potential upside of 18.37%. Fusion Pharmaceuticals has a consensus price target of $20.25, suggesting a potential downside of 5.37%. Given Twist Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Twist Bioscience is more favorable than Fusion Pharmaceuticals.
Twist Bioscience has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Fusion Pharmaceuticals has a beta of -0.72, meaning that its share price is 172% less volatile than the S&P 500.
Twist Bioscience has a net margin of -78.44% compared to Fusion Pharmaceuticals' net margin of -4,136.55%. Twist Bioscience's return on equity of -32.16% beat Fusion Pharmaceuticals' return on equity.
Summary
Twist Bioscience beats Fusion Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
